Table 1. The detailed characteristics between the NSCLC patients with/without BIM polymorphism (n = 245).
| Basic clinicopathologic factors | Total (n = 245) |
BIM deletion (n = 43) |
BIM wild-type (n = 202) |
p value |
|---|---|---|---|---|
| Age, mean ± SD | 58 ± 10 | 58 ± 10 | 58 ± 10 | 0.973 |
| Age | 0.862 | |||
| < 63 | 178 (73%) | 32 (74%) | 146 (72%) | |
| ≥ 63 | 67 (27%) | 13 (30%) | 54 (27%) | |
| Sex | 0.127 | |||
| Male | 74 (30%) | 10 (24%) | 64 (32%) | |
| Female | 171 (70%) | 33 (76%) | 138 (68%) | |
| Smoking history | 0.289 | |||
| Never | 184 (75%) | 31 (72%) | 153 (76%) | |
| Ever | 61 (25%) | 12 (28%) | 49 (24%) | |
| ECOG PS | 0.473 | |||
| 0–1 | 227 (93%) | 41 (95%) | 186 (92%) | |
| 2–4 | 18 (7%) | 2 (5%) | 16 (8%) | |
| Histology | 0.985 | |||
| Adenocarcinoma | 240 (98%) | 43 (100%) | 197 (97%) | |
| Squamous | 5 (2%) | 0 | 5 (3%) | |
| Stage | ||||
| IIIB | 12 (5%) | 0 | 12 (6%) | 0.063 |
| IV | 168 (68%) | 27 (63%) | 147 (70%) | |
| Postoperative recurrence | 65 (27%) | 16 (37%) | 49 (24%) | |
| No. of metastasis | 0.859 | |||
| 1–2 | 189 (77%) | 34 (79%) | 155 (77%) | |
| ≥ 3 | 56 (23%) | 9 (21%) | 47 (23%) | |
| EGFR mutation | 0.327 | |||
| Exon 19 deletion | 142 (58%) | 28 (65%) | 114 (56%) | |
| L858R mutation | 90 (37%) | 13 (30%) | 77 (38%) | |
| Others* | 13 (5%) | 2 (5%) | 11 (6%) | |
| EGFR TKIs | 0.272 | |||
| Gefitinib | 147 (60%) | 28 (65%) | 119 (59%) | |
| Erlotinib | 98 (40%) | 15 (35%) | 83 (40%) | |
| Line of EGFR TKIs | 0.621 | |||
| First | 86 (35%) | 16 (37%) | 70 (35%) | |
| Second | 97 (40%) | 18 (42%) | 79 (39%) | |
| Third line or later | 62 (25%) | 9 (21%) | 53 (26%) | |
| TKIs treatment response | 191 (78%) | 7 (16%) | 184 (91%) | 0.001 |
Note: *was refered as others mutation, included exon 18 point mutation, and complex mutation contained the deletion and missense mutation.